MedPath
Found 159 clinical trials|View Analysis
Sort by:

A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)

Phase 3
Not yet recruiting
Conditions
Ataxia-Telangiectasia
Ataxia-Telangiectasia (A-T)
Interventions
First Posted Date
2024-11-04
Last Posted Date
2024-11-04
Lead Sponsor
IntraBio Inc
Target Recruit Count
60
Registration Number
NCT06673056
Locations
🇺🇸

University of California Los Angeles, Los Angeles, California, United States

🇨🇭

University of Bern, Bern, Switzerland

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

Open-Label Extension of EryDex Study IEDAT-04-2022

Phase 3
Recruiting
Conditions
Ataxia Telangiectasia
Interventions
First Posted Date
2024-10-30
Last Posted Date
2024-12-20
Lead Sponsor
Quince Therapeutics S.p.A.
Target Recruit Count
106
Registration Number
NCT06664853
Locations
🇩🇪

University Hospital Frankfurt, Pediatric and Adolescent Clinic, Frankfurt, Germany

🇮🇹

Spedali Civili di Brescia, Pediatric immunology department, Brescia, Italy

🇩🇪

Tübingen University Hospital, Division Translational Genomics of Neurodegenerative Diseases, Tübingen, Bade-Würtenberg, Germany

and more 14 locations

Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects With Rosacea

Not Applicable
Recruiting
Conditions
Rosacea
Redness
Telangiectasia
Flushing
Pustular Acne
Papule Pruritic
Interventions
Other: SCARCr tester 1
Other: Placebo
First Posted Date
2024-09-03
Last Posted Date
2024-09-03
Lead Sponsor
NAOS Argentina S.A.
Target Recruit Count
40
Registration Number
NCT06582043
Locations
🇦🇷

Cirec Latam, Ciudad Autónoma de Buenos Aire, Argentina

🇧🇷

MEDCIN, São Paulo, Brazil

A Study to Determine the Safety and Efficacy of NT-501 With MHFM

Phase 3
Not yet recruiting
Conditions
Macular Telangiectasia Type 2
Interventions
Combination Product: NT-501 CNTF Implant
First Posted Date
2024-05-02
Last Posted Date
2024-07-25
Lead Sponsor
Neurotech Pharmaceuticals
Target Recruit Count
13
Registration Number
NCT06397131
Locations
🇺🇸

Retina Consultants of Texas, Bellaire, Texas, United States

🇺🇸

Bay Area Retina Associates, A Medical Group, Walnut Creek, California, United States

🇺🇸

Foundation for Vision Research, Grand Rapids, Michigan, United States

Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside

Not Applicable
Not yet recruiting
Conditions
Ataxia Telangiectasia
Interventions
First Posted Date
2024-03-22
Last Posted Date
2024-04-18
Lead Sponsor
The University of Queensland
Target Recruit Count
10
Registration Number
NCT06324877
Locations
🇦🇺

Queensland Children's Hospital, Brisbane, Queensland, Australia

Quality of Life in Patients With Hemorrhagic Telangiectasia

Conditions
Hereditary Hemorrhagic Telangiectasia
First Posted Date
2024-02-15
Last Posted Date
2024-02-15
Lead Sponsor
University Hospital, Essen
Target Recruit Count
250
Registration Number
NCT06261333
Locations
🇩🇪

Departement of Otorhinolaryngology - Head and Neck Surgery University Hospital Essen, Essen, NRW, Germany

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

Recruiting
Conditions
GastroIntestinal Bleeding
Telangiectasia
Cerebral Arteriovenous Malformations
Vascular Malformation
Epistaxis
Hereditary Hemorrhagic Telangiectasia
Arteriovenous Malformations
First Posted Date
2024-02-14
Last Posted Date
2024-08-27
Lead Sponsor
Cure HHT
Target Recruit Count
10000
Registration Number
NCT06259292
Locations
🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

Oregon Health and Science University, Portland, Oregon, United States

and more 12 locations

Evaluate the Neurological Effects of EryDex on Subjects With A-T

Phase 3
Recruiting
Conditions
Ataxia Telangiectasia
Interventions
First Posted Date
2024-01-05
Last Posted Date
2024-12-19
Lead Sponsor
Quince Therapeutics S.p.A.
Target Recruit Count
106
Registration Number
NCT06193200
Locations
🇺🇸

University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles, California, United States

🇺🇸

The Johns Hopkins Hospital, Division of pediatric allergy and immunology, Baltimore, Maryland, United States

🇺🇸

Cincinnati Children's Hospital, Division of neurology, Cincinnati, Ohio, United States

and more 16 locations

Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

Completed
Conditions
Hemorrhagic Hereditary Telangiectasia
HHT
Interventions
Other: bevacizumab treatment
First Posted Date
2023-09-15
Last Posted Date
2023-09-15
Lead Sponsor
Hospices Civils de Lyon
Target Recruit Count
23
Registration Number
NCT06039124
Locations
🇫🇷

CHU de Montpellier-Hôpital St Eloi, Montpellier, France

🇫🇷

Hôpital Ambroise Paré, Boulogne Billancourt, France

🇫🇷

Service de Médecine Interne et Maladies Vasculaires + Service Neuropédiatrie et neurochirurgie de l'enfant - CHU Angers, Angers, France

Efficiency of Determining the Clinical Class of Chronic Venous Disorders by Artificial Intelligence

Not Applicable
Recruiting
Conditions
Varicose Veins of Lower Limb
Telangiectasia
First Posted Date
2023-08-07
Last Posted Date
2024-08-20
Lead Sponsor
Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia
Target Recruit Count
1530
Registration Number
NCT05978986
Locations
🇷🇺

Vasculab ltd., Ekaterinburg, Russian Federation

🇷🇺

Phlebolog ltd., Perm, Russian Federation

🇷🇺

Azbuka zdoroviya ltd., Ekaterinburg, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath